BATM Advanced Communications Limited's () Zvi Marom speaks to Proactive London's Katie Pilbeam about their option agreement to sell its NGSoft software and digital services business for nearly US$34mln.
Marom explains that this deal will allow the company to focus on its areas of expertise which are cyber and biomedical. He goes on to discuss their COVID-19 kit which has been tested against the new SARS-CoV-2 variant - the virus that causes COVID-19.
He explains, the results confirm that it is effective in diagnosing this new strain.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of BATM Advanced Communications Ltd named herein, including the promotion by the Company of BATM Advanced Communications Ltd in any Content on the...
FOR OUR FULL DISCLAIMER CLICK HERE
